Breaking News, Collaborations & Alliances

Baxter Biopharma Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine

Manufacturing to take place at Baxter’s state-of-the-art Halle/Westfalen, Germany facility.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Baxter BioPharma Solutions has entered into an agreement to provide sterile manufacturing services for NVX-CoV2373, Novavax’ COVID-19 recombinant nanoparticle vaccine candidate with Matrix-M adjuvant. Baxter BioPharma Solutions is a contract manufacturing organization (CMO) that specializes in parenteral (injectable) pharmaceuticals, including vaccines. The agreement is expected to advance commercial-scale manufacturing essential for the vaccine’s production and distribution in the UK and Europe...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters